


Evacetrapib appears futile in high-risk vascular disease

May 31 2017



(HealthDay)—For patients with high-risk vascular disease, evacetrapib

does not affect the primary efficacy end point of first occurrence of any component of a composite of death from cardiovascular causes, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina, according to a study published in the May 18 issue of the *New England Journal of Medicine*.

A. Michael Lincoff, M.D., from the Cleveland Clinic, and colleagues enrolled 12,092 patients with high-risk vascular disease. Participants were randomized to receive evacetrapib or matching placebo daily, as well as standard medical therapy.

The researchers observed a 31.1 percent decrease in the mean [low-density lipoprotein cholesterol](#) level with evacetrapib versus a 6.0 percent increase with placebo at three months; 133.2 and 1.6 percent increases were seen in the mean high-density lipoprotein cholesterol levels with evacetrapib and placebo, respectively. The trial was terminated early due to lack of efficacy after 1,363 of the planned 1,670 primary end-point events had occurred. A primary end point occurred in 12.9 and 12.8 percent of patients in the evacetrapib and placebo groups, respectively, after a median of 26 months (hazard ratio, 1.01; 95 percent confidence interval, 0.91 to 1.11; P = 0.91)

"Although the cholesteryl ester transfer protein inhibitor evacetrapib had favorable effects on established lipid biomarkers, treatment with evacetrapib did not result in a lower rate of cardiovascular events than [placebo](#) among [patients](#) with high-risk vascular disease," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Eli Lilly, which manufactures evacetrapib and funded the study.

More information: [Abstract/Full Text \(subscription or payment may](#)

[be required](#))

Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: Evacetrapib appears futile in high-risk vascular disease (2017, May 31) retrieved 23 December 2022 from <https://medicalxpress.com/news/2017-05-evacetrapib-futile-high-risk-vascular-disease.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.